Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

381
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
381
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

338
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
338
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

484
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
484
Hormonal Regulation01:33

Hormonal Regulation

32.9K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
32.9K
Dialysis01:27

Dialysis

261
Renal failure occurs when the kidneys lose their ability to filter waste products from the blood effectively. It can be classified into two types: acute renal failure (ARF) and chronic renal failure (CRF).
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
261
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

135
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
135

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Pragmatic Low-Cost Digital Support Pathway for GDMT Optimization in Ambulatory HFrEF: An Exploratory 6-Month Matched Cohort Study.

Healthcare (Basel, Switzerland)·2026
Same author

Effects of Semaglutide on Cardiometabolic Risk in People with Obesity, With and Without Type 2 Diabetes: A Retrospective Observational Study.

Journal of clinical medicine·2026
Same author

Predicting Social Cognitive Outcomes in Adolescent-Onset Schizophrenia: A Hierarchical Analysis of Pharmacogenetic, Clinical, and Environmental Factors.

Journal of clinical medicine·2026
Same author

Clinical, Neuropathic, and Sudomotor Correlates of Orthostatic Hypotension in Type 2 Diabetes: A Cross-Sectional Study.

Healthcare (Basel, Switzerland)·2026
Same author

Quality of Life in Adolescents with Schizophrenia: The Importance of Social Cognition and Residual Psychopathology in the Context of CYP2D6 Polymorphism.

Healthcare (Basel, Switzerland)·2026
Same author

Depression as a Cardiovascular Risk Marker in Pregnancy: Hypertensive and Arrhythmic Maternal Outcomes in a Retrospective Matched Cohort.

Journal of clinical medicine·2026

Related Experiment Video

Updated: Jun 3, 2025

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.0K

Cardio-Renal Syndrome: Latest Developments in Device-Based Therapy.

Vlad Meche1, Nilima Rajpal Kundnani2,3, Abhinav Sharma2

  • 1Doctoral School, Faculty of Medicine, "Victor Babes" University of Medicine and Pharmacy, 3000041 Timisoara, Romania.

Journal of Clinical Medicine
|January 8, 2025
PubMed
Summary

Device-based therapies show promise for managing cardio-renal syndrome (CRS), improving heart and kidney function when traditional treatments fail. Further research is needed to optimize their role in patient care.

Keywords:
Acute Dialysis Quality Initiative (ADQI)cardio-renal syndrome (CRS)devicesheart failurekidney damage

More Related Videos

Early Detection of Drug-Induced Renal Hemodynamic Dysfunction Using Sonographic Technology in Rats
06:38

Early Detection of Drug-Induced Renal Hemodynamic Dysfunction Using Sonographic Technology in Rats

Published on: March 11, 2016

12.0K
A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program
04:24

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program

Published on: April 19, 2019

11.5K

Related Experiment Videos

Last Updated: Jun 3, 2025

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.0K
Early Detection of Drug-Induced Renal Hemodynamic Dysfunction Using Sonographic Technology in Rats
06:38

Early Detection of Drug-Induced Renal Hemodynamic Dysfunction Using Sonographic Technology in Rats

Published on: March 11, 2016

12.0K
A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program
04:24

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program

Published on: April 19, 2019

11.5K

Area of Science:

  • Cardiology
  • Nephrology
  • Biomedical Engineering

Background:

  • Cardio-renal syndrome (CRS) involves bidirectional heart and kidney dysfunction, often resistant to standard pharmacologic treatments.
  • Device-based therapies offer targeted interventions for hemodynamic and neurohormonal abnormalities in CRS.
  • This study categorizes device interventions using the DRI2P2S classification.

Purpose of the Study:

  • To evaluate the efficacy and safety of various device-based therapies in managing cardio-renal syndrome (CRS).
  • To assess the impact of devices on hemodynamic parameters, organ function, and patient symptoms.

Main Methods:

  • A systematic literature review (2004-2024) of clinical trials and observational studies on device therapies for CRS.
  • Analysis focused on hemodynamic endpoints, renal and cardiac function, symptom relief, and adverse events.
  • Included devices for pressure reduction, interstitial fluid management, and splanchnic denervation.

Main Results:

  • Device therapies demonstrated significant improvements in central venous pressure and diuretic responsiveness in acute CRS.
  • Observed benefits include stabilized renal function, reduced heart failure hospitalizations, and improved quality of life.
  • Challenges noted were procedure-related complications and a learning curve for device implantation.

Conclusions:

  • Device-based therapies are a valuable addition to CRS management, especially for treatment-resistant cases.
  • These devices target specific pathophysiological aspects of CRS, showing potential for improved clinical outcomes.
  • Further large-scale trials are necessary to define optimal patient selection and integrate these therapies into standard care.